NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
26/05/2026
Voltar para busca
Dado oficial do USPTO
A
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
26/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 45
Data de depósito
04/05/2023
Data de registro
26/05/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/05/2026
Última transação
26/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2014-02-00
Primeiro uso no comércio
2014-02-00
Código do desenho
3
Tipo de titular
03
Localização do titular
Vancouver, B.C., CA
Examinador
SIRIGNANO, EMMA MARIE
Unidade examinadora
M40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a circle with an "A" inside, with the horizontal line of the "A" having been replaced by a dot.
Titulares e representantes
Titulares
Acuitas Therapeutics, Inc.
Representantes
Karen Won Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsdrug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acidsmessenger RNA and lipid nanoparticles for treating cancergenetic disordersinfectious diseasescardiovascular diseasesliver diseasesautoimmune disordersneurological disordersmetabolic disorders; pharmaceutical preparationsvaccines for human use for treating cancerinfectious diseasescardiovascular diseasesliver diseasesautoimmune disordersneurological disordersmetabolic disordersgenetic disordersallergy; pharmaceutical preparations for gene silencingfor gene editingfor antibody therapeuticsfor protein replacement therapeuticsfor nucleic acid therapeuticsfor treating cancergenetic disordersinfectious diseasescardiovascular diseasesliver diseasesautoimmune disordersneurological disordersmetabolic disorders
Classe 42
Researchdevelopmentevaluation services in the fields of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid formulationslipid nanoparticlesnucleic acidsmessenger RNAdrug delivery agentsnucleic acid therapeuticssynthetic chemistry process technology; synthetic chemistry servicesdesignsynthesisanalysisevaluationbiophysical characterization of lipidslipid formulationslipid nanoparticles; preclinical study servicesconducting scientific feasibility studiespharmacodynamic and pharmacokinetic studiesscientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathologyimmune response characterization studiesbioanalytical services in the fields of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid formulationslipid nanoparticlesnucleic acidsmessenger RNAdrug delivery agentsnucleic acid therapeutics; scientific clinical research servicesin the fields of chemical molecular analysispharmaceutical product optimizationconducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for othersvaccines and nucleic acid therapeutics; research and development for others in the fields of new pharmaceuticalsmedical therapiesvaccinesgene therapiesdrug delivery agentsnucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid formulationslipid nanoparticlesnucleic acidsmessenger RNAdrug delivery agentsnucleic acid therapeuticssynthetic chemistry process technology; consultancy services in the fields of scientific research and development of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid formulationslipid nanoparticlesnucleic acidsmessenger RNAdrug delivery agentsnucleic acid therapeuticssynthetic chemistry process technology
Classe 45
Regulatory compliance consultancy services in the fields of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid nanoparticlesnucleic acidmessenger RNAdrug delivery agentsnucleic acid therapeuticssynthetic chemistry process technology
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
26/05/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/05/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/05/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/04/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/04/2026
DOCK
ASSIGNED TO EXAMINER
24/01/2026
IUAF
USE AMENDMENT FILED
17/10/2025
EISU
TEAS STATEMENT OF USE RECEIVED
17/10/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/04/2025
EX1G
SOU EXTENSION 1 GRANTED
22/04/2025
EXT1
SOU EXTENSION 1 FILED
22/04/2025
EEXT
SOU TEAS EXTENSION RECEIVED
22/04/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/12/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/12/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/12/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/12/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
22/10/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/10/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
18/10/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
18/10/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/08/2024
PUBO
PUBLISHED FOR OPPOSITION
27/08/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/08/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/07/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
18/07/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/07/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
18/07/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/07/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/05/2024
GNFR
FINAL REFUSAL E-MAILED
12/05/2024
CNFR
FINAL REFUSAL WRITTEN
12/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/04/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/04/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/04/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
26/01/2024
GNRT
NON-FINAL ACTION E-MAILED
26/01/2024
CNRT
NON-FINAL ACTION WRITTEN
26/01/2024
DOCK
ASSIGNED TO EXAMINER
26/01/2024
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/06/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/06/2023
NWAP
NEW APPLICATION ENTERED
08/05/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace A ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.